HBK Investments L P Takes Position in Pediatrix Medical Group, Inc. (NYSE:MD)

HBK Investments L P bought a new stake in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 20,811 shares of the company's stock, valued at approximately $273,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MD. Pacer Advisors Inc. acquired a new stake in Pediatrix Medical Group in the 4th quarter valued at $35,492,000. American Century Companies Inc. increased its holdings in Pediatrix Medical Group by 628.2% in the 4th quarter. American Century Companies Inc. now owns 1,739,323 shares of the company's stock valued at $22,820,000 after purchasing an additional 1,500,485 shares in the last quarter. Oberweis Asset Management Inc. acquired a new stake in Pediatrix Medical Group in the 4th quarter valued at $6,122,000. Renaissance Technologies LLC increased its holdings in Pediatrix Medical Group by 117.4% in the 4th quarter. Renaissance Technologies LLC now owns 838,800 shares of the company's stock valued at $11,005,000 after purchasing an additional 453,000 shares in the last quarter. Finally, Boston Partners increased its holdings in Pediatrix Medical Group by 25.2% in the 4th quarter. Boston Partners now owns 1,956,353 shares of the company's stock valued at $25,922,000 after purchasing an additional 393,600 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Truist Financial lowered their price target on Pediatrix Medical Group from $18.00 to $16.00 and set a "hold" rating for the company in a report on Friday, April 11th. StockNews.com raised Pediatrix Medical Group from a "hold" rating to a "buy" rating in a report on Wednesday, January 22nd. Finally, UBS Group upped their target price on Pediatrix Medical Group from $16.50 to $18.50 and gave the company a "neutral" rating in a research report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $16.75.

Pediatrix Medical Group Stock Performance

MD stock traded up $0.02 during trading on Wednesday, reaching $12.58. 133,652 shares of the company's stock were exchanged, compared to its average volume of 837,748. The company has a quick ratio of 1.42, a current ratio of 1.60 and a debt-to-equity ratio of 0.81. Pediatrix Medical Group, Inc. has a 1-year low of $6.62 and a 1-year high of $17.67. The company's fifty day moving average price is $13.91 and its 200-day moving average price is $13.98. The firm has a market cap of $1.08 billion, a PE ratio of -10.48, a P/E/G ratio of 1.74 and a beta of 1.32.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.12. The business had revenue of $502.36 million during the quarter, compared to analyst estimates of $486.22 million. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. On average, research analysts expect that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.